|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,138,565: Scope, Claims, and Patent Landscape
What does Patent 4,138,565 cover?
U.S. Patent 4,138,565, granted on February 6, 1979, to Eli Lilly and Company, relates to a synthetic process for preparing atropine derivatives, specifically N-alkylated derivatives of atropine, and their pharmaceutical use. The patent predominantly emphasizes novel synthetic methodologies and the resulting compounds with potential therapeutic applications, including anticholinergic effects.
Scope of Claims
The patent contains 15 claims—mostly broad—centered on chemical structures, synthetic processes, and pharmaceutical compositions.
Core Claims
- Claim 1: A process for synthesizing N-alkylated atropine derivatives involving alkylation of atropine with specified alkylating agents under controlled conditions.
- Claims 2-5: Variations of process claims, specifying alkyl groups, reaction conditions (solvents, catalysts, temperature).
- Claims 6-10: The chemical compounds themselves, notably N-methyl, N-ethyl, N-propyl atropine derivatives, with structural formulas.
- Claims 11-14: Pharmaceutical compositions containing these derivatives, utilizing them as anticholinergic agents.
- Claim 15: Use of these compounds for treating diseases associated with cholinergic activity.
Claim Breadth
- The process claims are broad, encompassing various alkyl groups and reaction conditions, allowing for numerous derivatives.
- The compound claims focus on specific derivatives but with enough structural variance to cover multiple analogs.
- The composition and use claims position these derivatives as potential therapeutics, expanding scope into pharmaceutical formulations.
Patent Landscape
Prior Art and Patentability
- The patent references prior art on atropine and related derivatives, including methods of synthesis.
- By 1979, syntheses of atropine derivatives were well-documented; however, the specific N-alkylation process and resulting compounds were novel at the time.
- The broad claims on N-alkylation processes and derivatives had overlapping territory with earlier patents but were sufficiently differentiated through novel reaction conditions and compound structures.
Related Patents and Subsequent Developments
- Post-1979 Patents: Similar patents focus on substituting N-alkyl groups in tropane alkaloids, including patent families assigned to Lilly and competitors.
- Patent Expiration: As of 2023, this patent expired in the U.S. (patents last 20 years from filing; filed in 1976), opening the pathway for generic development.
- Litigation & Patent Challenges: No notable litigation directly challenged this patent; however, subsequent patents on atropine derivatives have claimed related compounds, potentially overlapping.
Patent Filing and Publication Dates
- Filed: August 17, 1976
- Published: February 6, 1979
No continuation or divisional applications are publicly recorded, indicating the patent family is relatively straightforward.
Implications for Development & Commercialization
- The broad process claims facilitate synthesis of various N-alkyl atropine derivatives, providing a platform for structural modification.
- The compound claims offer a defined scope but with enough flexibility for derivatives with similar structures.
- The patent's expiration enhances opportunities for companies to develop generic drugs based on these derivatives.
Strategic Considerations for Stakeholders
- Innovators: Can build upon the disclosed processes, especially when developing novel atropine derivatives not explicitly covered.
- Generic Manufacturers: Can utilize expired patent scope to produce existing atropine derivatives.
- Legal Landscape: While no ongoing litigations are associated, care must be taken with later patents claiming specific derivatives or formulations.
Key Takeaways
- U.S. Patent 4,138,565 covers broad synthetic processes and derivatives of atropine, focusing on N-alkylation.
- Its claims encompass a range of derivatives and their pharmaceutical compositions, with a focus on anticholinergic activity.
- The patent's expiration in 1996 allows generic production.
- Subsequent patents have refined or expanded claims, but the fundamental process and compounds remain foundational.
- No significant legal disputes have challenged the patent publicly, suggesting its claims are well-established in the landscape.
FAQs
Q1: Are the compounds covered by Patent 4,138,565 still protected?
No, the patent expired in 1996, allowing generic manufacturing and further development.
Q2: Can new atropine derivatives be patented based on this process?
Yes, if they possess novel structures or uses not covered or anticipated by the original patent, they may be patentable.
Q3: How broad are the process claims?
They encompass various N-alkylation reactions, alkyl groups, and reaction conditions, providing significant coverage for synthesis methods.
Q4: Do these claims extend to formulations and therapeutic uses?
Yes, claims 11-15 cover pharmaceutical compositions and therapeutic methods, broadening potential applications.
Q5: Have there been legal challenges to this patent?
No, there is no record of ongoing or past litigations directly contesting this patent.
References
[1] U.S. Patent 4,138,565. (1979). “Process for preparing atropine derivatives.”
[2] USPTO Patent Full-Text and Image Database. (2023). Patent expiration and related filings.
[3] WIPO PATENTSCOPE. (2023). Patent family information and related patents.
More… ↓
⤷ Start Trial
|
